CorMedix Inc. (NYSEMKT:CRMD) a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease and infectious disease, announces the receipt of a notice indicating that CorMedix did not meet certain of the NYSE MKT LLC’s (the “NYSE MKT”) continued listing standards as set forth in the NYSE MKT Company Guide (“Company Guide”). CorMedix Inc. (NYSEMKT:CRMD) weekly performance is -15.48%. On last trading day company shares ended up $1.31. CorMedix Inc. (NYSEMKT:CRMD) distance from 50-day simple moving average (SMA50) is -35.20%.
OvaScienceSM, (NASDAQ:OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, on 8 may reported first quarter 2014 financial results, and highlighted recent accomplishments. Net loss for the three months ended March 31, 2014 was $7.8 million, or ($0.41) per share, as compared to net loss of $5.2 million, or ($0.39) per share, for the three months ended March 31, 2013. The increase for the quarter was primarily attributable to $1.0 million in license fees, higher personnel costs, greater development expenses, and stock-based compensation expense. OvaScience Inc. (NASDAQ:OVAS) shares fell -7.87% in last trading session and ended the day on $7.14. OVAS return on assets is -51.20%.OvaScience Inc. (NASDAQ:OVAS) quarterly performance is -28.67%.
Equities researchers at Wedbush began coverage on shares of Cerulean Pharma (NASDAQ:CERU) in a research report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $12.00 price target on the stock. Wedbush’s price target would indicate a potential upside of 78.04% from the stock’s previous close. Cerulean Pharma Inc. (NASDAQ:CERU) shares moved down -8.64% in last trading session and was closed at $5.71, while trading in range of $5.05 – $6.34. Cerulean Pharma Inc. (NASDAQ:CERU) year to date (YTD) performance is -16.64%.
Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) announced on 15 may Net loss attributable to common stockholders for the three months ended March 31, 2014 was $(2,325,163), or $(0.26), per basic and diluted share, compared to a net loss attributable to common stockholders for the three months ended March 31, 2013 of $(1,465,481), or $(0.19), per basic and diluted share. Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) ended the last trading day at $5.73. Company weekly volatility is calculated as 14.68% and price to cash ratio as 3.32.Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) showed a positive weekly performance of 6.90%.